Infinity Pharmaceuticals Inc. (INFI): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Infinity Pharmaceuticals ( INFI) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.3%. By the end of trading, Infinity Pharmaceuticals fell $0.58 (-3.0%) to $18.53 on average volume. Throughout the day, 2,155,089 shares of Infinity Pharmaceuticals exchanged hands as compared to its average daily volume of 1,666,300 shares. The stock ranged in price between $17.92-$19.46 after having opened the day at $19.11 as compared to the previous trading day's close of $19.11. Other companies within the Drugs industry that declined today were: Senesco Technologies ( SNTI), down 12.5%, Vanda Pharmaceuticals ( VNDA), down 11.0%, Vermillion ( VRML), down 9.8% and Hemispherx Biopharma ( HEB), down 9.4%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

Infinity Pharmaceuticals, Inc., a drug discovery and development company, focuses on discovering, developing, and delivering medicines to patients for diseases with significant unmet need. Infinity Pharmaceuticals has a market cap of $970.0 million and is part of the health care sector. Shares are down 42.1% year to date as of the close of trading on Wednesday. Currently there are 6 analysts that rate Infinity Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Infinity Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, weak operating cash flow and poor profit margins.

On the positive front, Skystar Bio-Pharmaceutical Company ( SKBI), down 20.3%, Synthetic Biologics ( SYN), down 19.4%, Chelsea Therapeutics International ( CHTP), down 13.3% and Durect Corporation ( DRRX), down 12.9% , were all gainers within the drugs industry with Regeneron Pharmaceuticals ( REGN) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Don't Tell Anyone: Insiders Are Buying These Stocks Like Crazy

5 Stocks Insiders Love Right Now

Infinity Pharmaceuticals (INFI) Stock Rises on 'Favorable' Cancer Drug Trial Results

7 Stocks Under $10 to Trade for Big Post-Brexit Gains

Infinity Pharmaceuticals (INFI) Highlighted As Weak On High Volume